We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

136 hedge funds and large institutions have $2.34B invested in MoonLake Immunotherapeutics in 2025 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 33 increasing their positions, 43 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

141% more call options, than puts

Call options by funds: $21.1M | Put options by funds: $8.78M

140% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 15

18% more funds holding

Funds holding: 115 → 136 (+21)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

5.92% less ownership

Funds ownership: 100.57% → 94.65% (-5.9%)

23% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 43

32% less capital invested

Capital invested by funds: $3.43B → $2.34B (-$1.09B)

Holders
136
Holders Change
+21
Holders Change %
+18.26%
% of All Funds
1.82%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
36
Increased
33
Reduced
43
Closed
15
Calls
$21.1M
Puts
$8.78M
Net Calls
+$12.3M
Net Calls Change
+$9.63M

Top Buyers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
+$15.1M
2
Millennium Management
Millennium Management
New York
+$14.8M
3
OCA
Octagon Capital Advisors
New York
+$12.8M
4
VPC
Vestal Point Capital
New York
+$8.62M
5
Franklin Resources
Franklin Resources
California
+$8.25M

Top Sellers

Rank Fund Capital Flow
1
Holocene Advisors
Holocene Advisors
New York
-$60.2M
2
PBA
Paradigm Biocapital Advisors
New York
-$49.3M
3
Citadel Advisors
Citadel Advisors
Florida
-$30.5M
4
Marshall Wace
Marshall Wace
United Kingdom
-$26M
5
EC
EcoR1 Capital
California
-$18M
Name Holding Trade Value Shares
Change 		Change in
Stake
LPL Financial
101
LPL Financial
California
$346K +$30.2K +701 +9%
XT
102
XTX Topco
Cayman Islands
$332K +$366K +8,495 New
BC
103
Birchview Capital
Vermont
$313K +$172K +4,000 +100%
New York State Common Retirement Fund
104
New York State Common Retirement Fund
New York
$273K +$301K +6,992 New
GT
105
Glenmede Trust
Pennsylvania
$261K +$288K +6,690 New
ASRS
106
Arizona State Retirement System
Arizona
$247K -$1.68K -39 -0.6%
BNP Paribas Financial Markets
107
BNP Paribas Financial Markets
France
$247K -$56.2K -1,305 -17%
LCM
108
Legato Capital Management
California
$240K +$265K +6,142 New
Teacher Retirement System of Texas
109
Teacher Retirement System of Texas
Texas
$232K -$25.5K -592 -9%
Russell Investments Group
110
Russell Investments Group
United Kingdom
$213K -$2.17M -50,430 -90%
ACM
111
ADAR1 Capital Management
Texas
$212K -$517K -12,000 -69%
KK
112
KLP Kapitalforvaltning
Norway
$176K – – –
AAM
113
Advisors Asset Management
Colorado
$157K +$77.7K +1,803 +82%
VIA
114
Virtus Investment Advisers
Connecticut
$119K +$131K +3,050 New
BG
115
Bellevue Group
Switzerland
$117K -$60.3K -1,400 -32%
Zurich Cantonal Bank
116
Zurich Cantonal Bank
Switzerland
$108K – – –
QL
117
Quarry LP
New York
$93.8K +$103K +2,400 New
US Bancorp
118
US Bancorp
Minnesota
$86.3K +$50.8K +1,178 +114%
Deutsche Bank
119
Deutsche Bank
Germany
$35.3K – – –
JP Morgan Chase
120
JP Morgan Chase
New York
$32.9K -$17.6K -409 -33%
Wells Fargo
121
Wells Fargo
California
$28.3K +$17.2K +400 +123%
PTC
122
Private Trust Company
Ohio
$7.54K – – –
CIAM
123
Caitong International Asset Management
Hong Kong
$5.74K +$6.33K +147 New
TRCT
124
Tower Research Capital (TRC)
New York
$5.7K +$6.29K +146 New
WPA
125
Wealth Preservation Advisors
Tennessee
$4.69K +$5.17K +120 New
3 4
5
6 7

MLTX Hedge Fund Activity: Q1 2025 in Review

136 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q1 2025, worth a combined $2.34B — down 32% from $3.43B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new MLTX positions and 15 closed out — a net gain of 21 holders — while 33 added to existing stakes and 43 trimmed.

The largest buyer was Logos Global Management, opening a new position worth an estimated $15.1M. The largest seller was Holocene Advisors, cutting an estimated $60.2M.

  • 136 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q1 2025, up from 115 in Q4 2024.
  • Funds reported $2.34B of MoonLake Immunotherapeutics stock for Q1 2025, down 32% quarter-over-quarter.
  • 36 funds opened new MoonLake Immunotherapeutics positions in Q1 2025 and 15 closed out, a net change of +21 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q1 2025 was Logos Global Management, an estimated $15.1M added.
  • The largest MoonLake Immunotherapeutics seller in Q1 2025 was Holocene Advisors, an estimated $60.2M sold.

Based on aggregated 13F filings for Q1 2025.